Zheng Quan Shi Bao Wang·2025-08-06 12:15Core Insights - BeiGene reported strong financial performance for Q2 2025, achieving total revenue of 17.518 billion RMB, a year-on-year increase of 46.0% [1] - The company turned profitable with an operating profit of 799 million RMB and a net profit attributable to shareholders of 450 million RMB, marking a significant turnaround from losses in the previous year [1] - BeiGene updated its revenue guidance for the full year 2025, now expecting revenue between 35.8 billion RMB and 38.1 billion RMB, with a gross margin forecast of 80% to 90% [1] Financial Performance - Total revenue for the first half of 2025 reached 17.518 billion RMB, with product revenue at 17.360 billion RMB, reflecting a growth of 45.8% compared to the previous year [1][2] - The sales of the BTK inhibitor, Zebrutinib, reached 12.527 billion RMB in the first half of 2025, a 56.2% increase year-on-year, with U.S. sales contributing 8.958 billion RMB, up 51.7% [3] - The PD-1 inhibitor, Tislelizumab, generated sales of 2.643 billion RMB, a 20.6% increase, driven by new indications approved for reimbursement in China [3] Product Development and Market Position - BeiGene's CEO emphasized the company's commitment to sustainable growth and its leading position in the global oncology market, particularly with its core product, Tislelizumab [2] - The company is advancing two additional blood cancer products in Phase 3 clinical trials, with key data expected soon, which will further strengthen its market position [2] - BeiGene plans to achieve over 20 research milestones in the next 18 months, indicating a robust pipeline in both hematologic and solid tumor treatments [2]